Loading stock data…
Fennec Pharmaceuticals Inc (FENC)
$11.03+0.01 (+0.09%)
After Hours$11.03+0.00 (+0.00%)· Last close Jun 29
Fennec Pharmaceuticals Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Fennec Pharmaceuticals Inc. in the Healthcare sector is trading at $11.03 with a market capitalization of $315M. Wall Street consensus targets $15.67 (6 analysts), implying a +42.0% move over the next 12 months. The stock is currently near its 52-week high of $11.31, remaining 36.5% above its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +42.0% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $15.11M↑ | $13.78M↑ | $12.46M↑ | $9.65M↑ | $8.75M |
| Gross Profit | $14.54M↑ | $12.01M↑ | $11.80M↑ | $8.69M↑ | $8.38M |
| Operating Income | -$119,000↑ | -$2.58M↓ | -$201,000↑ | -$2.73M↓ | -$821,000 |
| Net Income | $201,000↑ | -$4.79M↓ | -$638,000↑ | -$3.15M↓ | -$1.17M |
Peer Comparison
JNJUNHPFE
Fundamentals
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pedia...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$314.72M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-22.23%
Volume
Today's trading volume
232,020
Recent News
Insider Favorites High Growth Companies June 2026
Over the last 7 days, the United States market has dropped 2.5%, yet it remains up by 23% over the past year, with earnings projected to grow by 17% annually in the coming years. In this fluctuating environment, identifying growth companies with high insider ownership can be particularly appealing as these firms often demonstrate strong potential and a vested interest from those who know them best.
Adherex Technologies’ PEDMARK Push Targets Larger AYA Market After Record Quarter
Fennec Pharmaceuticals (NASDAQ:FENC) executives outlined the company’s commercial strategy for PEDMARK, its sodium thiosulfate product used to prevent cisplatin-related hearing loss, during a fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference. Ram Selvaraju, managing dir
Fennec Announces New Research Supporting Pedmark's Use at ASCO Annual Meeting
Fennec Pharmaceuticals (FRX.TO) said on Friday that new research evaluating Pedmark (sodium thiosulf
Fennec Pharmaceuticals Inc (FENC) Q1 2026 Earnings Call Highlights: Record Sales Surge and ...
Fennec Pharmaceuticals Inc (FENC) reports a 73% increase in net product sales and outlines strategic expansions despite rising operating expenses.
Fennec Pharmaceuticals Inc. Q1 2026 Earnings Call Summary
Moby summary of Fennec Pharmaceuticals Inc.'s Q1 2026 earnings call